Free Trial
LON:RENX

Renalytix (RENX) Share Price, News & Analysis

Renalytix logo
GBX 8.50 -0.50 (-5.56%)
As of 03/28/2025 12:16 PM Eastern

About Renalytix Stock (LON:RENX)

Key Stats

Today's Range
8.50
9.22
50-Day Range
8.50
12
52-Week Range
6.50
35
Volume
718,265 shs
Average Volume
268,225 shs
Market Capitalization
£35.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

Remove Ads
Receive RENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter.

RENX Stock News Headlines

Renalytix Plc (RTNXF)
Your Wealth is Under Attack
Please don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.
Renalytix Successfully Passes All Resolutions at AGM
Renalytix Advances Strategic Goals with Funding and Market Expansion
Renalytix Leadership Engages in Notable Share Transactions
Renalytix Appoints Robert Naylor to Boost Strategic Growth
Renalytix Strengthens Leadership with New Director
See More Headlines

RENX Stock Analysis - Frequently Asked Questions

Renalytix's stock was trading at GBX 11 at the beginning of 2025. Since then, RENX shares have decreased by 22.7% and is now trading at GBX 8.50.
View the best growth stocks for 2025 here
.

Renalytix Plc (LON:RENX) released its earnings results on Tuesday, October, 1st. The company reported ($31.00) earnings per share (EPS) for the quarter. Renalytix had a negative net margin of 1,191.75% and a positive trailing twelve-month return on equity of 293.20%.

Shares of RENX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Renalytix investors own include AutoZone (AZO), Beyond Meat (BYND), Helium One Global (HE1), HSBC (HSBA), Intel (INTC), ITM Power (ITM) and JD Sports Fashion (JD).

Company Calendar

Last Earnings
10/01/2024
Today
3/28/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Health Information Services
Sub-Industry
N/A
Current Symbol
LON:RENX
CIK
N/A
Fax
N/A
Employees
102
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-109,928,962.31
Net Margins
-1,191.75%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£9.22 million
Cash Flow
GBX 4.63 per share
Price / Cash Flow
1.84
Book Value
GBX (10.71) per share
Price / Book
-0.79

Miscellaneous

Free Float
N/A
Market Cap
£35.23 million
Optionable
Not Optionable
Beta
2.10
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (LON:RENX) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners